Gapping up
In reaction to earnings/guidance:
- ORCL +5.8%, BUR +1.3%, IAS +1.3% (guidance), THS +0.8% (guidance), HD +0.6% (reaffirms FY23 guidance)
Other news:
- SAND +5.7% (will remain in NYSE Arca Gold Miners Index)
- TM +4.5% (to launch solid-state-battery EVs by 2027 according to Nikkei)
- SGH +3.4% (to divest majority stake of SMART modular Brazil)
- ABOS +2.5% (to present topline results from first-in-human phase 1 study of ACU193 for early Alzheimer's disease during featured research session at the Alzheimer's Association International Conference)
- IRWD +2.4% (FDA approval of new indication for LINZESS)
- UVE +1.9% (new $20 mln repurchase program)
- OVV +1.3% (total production updates)
- TEVA +1.1% (settles Kentucky price-fixing claim)
- HOG +0.9% (issues statement regarding production suspension)
- SGEN +0.9% (ADCETRIS (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma)
Analyst comments:
- DVN +1.5% (upgraded to Buy from Neutral at Goldman)
- EGP +1% (upgraded to Buy from Neutral at Citigroup)
- AIZ +0.9% (upgraded to Overweight from Neutral at Piper Sandler)
- ULTA +0.7% (upgraded to Buy from Hold at Loop Capital)